Glutathione S-transferase M1 status and breast cancer risk: A meta-analysis

Yonsei Medical Journal

Volumn 45, Issue 4, 2004, Pages 683-689

  Sull, Jae Woong ^a   Ohrr, Heechoul ^b   Kang, Dae Ryong ^b   Nam, Chung Mo ^b  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Breast cancer; GSTM1; Polymorphism

Indexed keywords

GLUTATHIONE TRANSFERASE;

AGE; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; ENZYME DEFICIENCY; ENZYME POLYMORPHISM; ETHNOLOGY; FEMALE; GENE FREQUENCY; HAPLOTYPE; HIGH RISK POPULATION; HUMAN; INFORMATION PROCESSING; MEDLINE; POSTMENOPAUSE; PUBLICATION; RISK ASSESSMENT;

EID: 4644282745     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2004.45.4.683     Document Type: Article

References (28)

1. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000;321:624-8.
2. Cui J, Antoniou AC, Dite GS, Southey MC, Venter DJ, Easton DF, et al. After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer. Am J Hum Genet 2001;68:420-31.
3. Smith G, Stanley LA, Sim E, Strange RC, Wolf CR. Metabolic polymorphisms and cancer susceptibility. Cancer Surv 1995;25:27-65.
4. Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 1993;14:1821-4.
5. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, et al. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res 1995;55:3483-5.
6. Kelsey KT, Hankinson SE, Colditz GA, Springer K, Garcia-Closas M, Spiegelman D, et al. Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases. Cancer Epidemiol Biomarkers Prev 1997,6:511-5.
7. Helzlsouer KJ, Selmin O, Huang HY, Strickland PT, Hoffman S, Alberg AJ, et al. Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J Natl Cancer Inst 1998;90:512-8.
8. Charrier J, Maugard CM, Le Mevel B, Bignon YJ. Allelotype influence at glutathione S-transferase M1 locus on breast cancer susceptibility. Br J Cancer 1999; 79:346-53.
9. Garcia-Closas M, Kelsey KT, Hankinson SE, Spiegelman D, Springer K, Willett WC, et al. Glutathione S-transferase mu and theta polymorphisms and breast cancer susceptibility. J Natl Cancer Inst 1999;91:1960-4.
10. Curran JE, Weinstein SR, Griffiths LR. Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and breast cancer susceptibility. Cancer Lett 2000;153:113-20.
11. Millikan R, Pittman G, Tse CK, Savitz DA, Newman B, Bell D. Glutathione S-transferases M1, T1, and P1 and breast cancer. Cancer Epidemiol Biomarkers Prev 2000; 9:567-73.
12. Park SK, Yoo KY, Lee SJ, Kim SU, Ahn SH, Noh DY, et al. Alcohol consumption, glutathione S-transferase M1 and T1 genetic polymorphisms ahd breast cancer risk. Pharmacogenetics 2000;10:301-9.
13. Krajinovic M, Ghadirian P, Richer C, Sinnett H, Gandini S, Perret C, et al. Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. Int J Cancer 2001;92:220-5.
14. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, et al. Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer. Cancer Epidemiol Biomarkers Prev 2001;10:229-36.
15. Gudmundsdottir K, Tryggvadottir L, Eyfjord JE. GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene. Cancer Epidemiol Biomarkers Prev 2001;10: 1169-73.
16. Zheng W, Wen WQ, Gustafson DR, Gross M, Cerhan JR, Folsom AR. GSTM1 and GSTT1 polymorphisms and postmenopausal breast cancer risk. Breast Cancer Res Treat 2002;74:9-16.
17. da Fonte de Amorim L, Rossini A, Mendonca G, Lotsch P, de Almeida Simao T, deMoura Gallo C, et al. CYP1A1, GSTM1, and GSTT1 polymorphisms and breast cancer risk in Brazilian women. Cancer Lett 2002;181:179-86.
18. Zheng T, Holford TR, Zahm SH, Owens PH, Boyle P, Zhang Y, et al. Cigarette smoking, glutathione-s-transferase M1 and t1 genetic polymorphisms, and breast cancer risk (United States). Cancer Causes Control 2002;13:637-45.
19. Matheson MC, Stevenson T, Akbarzadeh S, Propert DN. GSTT1 null genotype increases risk of premenopausal breast cancer. Cancer Lett 2002;181:73-9.
20. van der Hel OL, Peeters PH, Hein DW, Doll MA, Grobbee DE, Kromhout D, et al. NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. Pharmacogenetics 2003;13:399-407.
21. Khedhaier A, Remadi S, Corbex M, Ahmed SB, Bouaouina N, Mestiri S, et al. Glutathione S- transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma. Br J Cancer 2003;20;89:1502-7.
22. Egan KM, Cai Q, Shu XO, Jin F, Zhu TL, Dai Q, et al. Genetic polymorphisms in GSTM1, GSTP1, and GSTT1 and the risk for breast cancer: results from the Shanghai Breast Cancer Study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2004;13:197-204.
23. Roodi N, Dupont WD, Moore JH, Parl FF. Association of homozygous wild-type glutathione S-transferase M1 genotype with increased breast cancer risk. Cancer Res 2004;64:1233-6.
24. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SD, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: analysis and examples. Br J Cancer 1977;35:1-39.
25. Peto R. Why do we need systematic overviews of randomized trials? Stat Med 1987;6:233-40.
26. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:843-54.
27. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993;85:892-7.
28. Cui J, Antoniou AC, Dite GS, Southey MC, Venter DJ, Easton DF, et al. After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer. Am J Hum Genet 2001;68:420-31.